The relevance of long-term adherence to non-pharmacological and pharmacological treatment of hypertension

Current Hypertension Reviews

Volumn 3, Issue 3, 2007, Pages 203-207

  Waeber, Bernard ^a   Feihl, François ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antihypertensive therapy; Blood pressure control; Compliance; Cost effectiveness; Persistence; Tolerability; Treatment withdrawal

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; THIAZIDE DIURETIC AGENT;

ALCOHOL ABSTINENCE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW FAT DIET; META ANALYSIS; MONOTHERAPY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 34547849470     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340207781386729     Document Type: Review

References (47)

1. Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45: 813-827.
2. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
3. Chobanian AV, Bakris GL, Black HR, et al., Seventh report of the Joint National Committee on Prevenfion, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
4. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17.
5. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Pressure 2001; 10: 62-73.
6. Staessen J, Fagard R, Lijnen P, Amery A. Body weight, sodium intake and blood pressure. J Hypertens 1989; 7 (suppl 1): 19.
7. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports Exerc 2001; 33 (suppl): 484-492.
8. Neaton JD, Grimm RH, Jr., Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-724.
9. Roel JP, Bildebrant CL, Grimm RH, Jr. Quality of life with non-pharmacologic treatment of hypertension. Current Hypertens Rep 2001; 3: 446-472.
10. Nicolson DJ, Dickinson HO, Campbell F, Mason JM. Lifestyle interventions or drugs for patients with essential hypertension: a systematic review. J Hypertens 2004; 22: 2043-2048.
11. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exper Hypertens 1999; 21: 973-985.
12. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345-356.
13. Wetzels GE, Nelemans P, Schouten JS, Prins MR. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849-1855.
14. Andrejak M, Genes N, Vaurt, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the eviluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens 2000; 13: 184-190.
15. Detry JM, Block P, De Backer G, Degaute JP. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. Eur J Clin Pharmacol 1995; 47: 447-481.
16. Girvin B, McDermott BJ, Johnston GD. A comparison of of enalapril 20 mg once daily versus 10 mg twice daily in terms of blood pressure lowering and patient-compliance. J Hypertens 1999; 17: 1627-1631.
17. Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997; 13: 914-920.
18. Mounier-Vehier C, Bernaud C, Carre A, Lequeuche B, Hotton JM, Charpentier JC. Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am J Hypertens 1998; 11: 487-486.
19. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
20. Dickerson CJE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-2013.
21. Waeber B, Vetter W, Darioli R, Keller U, Brunner HR. Improved blood pressure control by monitoring compliance with antihypertensive therapy. Int J Clin Pract 1999; 53: 37-38.
22. Burnier M, Schneider MP, Chiolero A, Fallab-Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: The basis for rational therapeutic decision. J hypertens 2007; 19: 335-341.
23. Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 2004; 13: 11-19.
24. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004; 19: 357-362.
25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibition or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2977.
26. Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol 2004; 20: 417-421.
27. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II recepior antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.
28. Degli EL, Degli EE, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24; 1347-1357.
29. Mazzaglia G, Mantovani LG, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093-2100.
30. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmcother 2005; 39: 1401-1408.
31. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006, 24: 1193-1200.
32. Van Wijk BL., Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101-2107.
33. Law, MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: anlysis of 354 randomised trials. BMJ 2003; 326: 1427-1431.
34. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Managing Care 2000; 9 (Suppl.): 2-6.
35. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31-37.
36. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
37. Brunner HR, Menard J, Waeber B, et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3-11.
38. Lip GY, Beevers GD. Doctors, nurses, pharmacists and patients. The Rational Evaluation and Choice in Hypertension (REACH) survey of hypertension care delivery. Blood Pressure 1997; 6(suppl 1):6-10.
39. Dusing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy - the role of adverse effects and compliance. Blood Pressure 1998; 7: 313-315.
40. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Patterns of hypertension management in Italy: results of a pbarmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18: 1691-1699.
41. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004; 22: 1831-1837.
42. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 533-537.
43. Urquhart J. Some economic consequences of noncompliance. Current Hypertens Rep 2001; 3: 473-480.
44. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19: 1446-1457.
45. Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics 2001; 19: 337-347.
46. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
47. Krousel-Wood M, Hyre A, Muntner P, Morisky D. Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr Opin Cardiol 2005; 20: 296-300ces.